

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October, 2024

Commission File No. 001-39621

---

**OPTHEA LIMITED**  
(Translation of registrant's name into English)

---

Level 4  
650 Chapel Street  
South Yarra, Victoria, 3141  
Australia  
(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  
Form 20-F ☒ Form 40-F ☐

---

---

## EXHIBIT INDEX

| Exhibit | Description                                                                               |
|---------|-------------------------------------------------------------------------------------------|
| 99.1    | <a href="#">Press Release - Opthea Wet AMD Program to be Presented at Innovate Retina</a> |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

**OPTHEA LIMITED**

(Registrant)

By: /s/ Frederic Guerard

Name: Frederic Guerard

Title: Chief Executive Officer

Date: 10/10/2024

---

**ASX, Nasdaq and Media Release**

October 10, 2024

**Opthea Wet AMD Program to be Presented at Innovate Retina**

**Melbourne, Australia, and Princeton, NJ, US, October 10, 2024--** Opthea Limited (ASX/NASDAQ:OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois.

David Boyer, MD, will present an update on Opthea's wet AMD program, including highlights of the unmet medical need in wet AMD, the sozinibercept Phase 2b trial results, and the Phase 3 program designed to assess superiority in visual acuity of the combination therapy with sozinibercept over anti-VEGF-A monotherapy.

Details are as follows:

**Session 4:** New Routes and New Molecules

**Timing:** Thursday, October 17, 2024, 5:27 PM CT

**Presentation:** Update on OPT-302 (sozinibercept)

**Presenter:** David S. Boyer, MD

**Agenda:** <https://retinainnovate.com/agenda/>

Innovate Retina focuses exclusively on game-changing innovations in medical and surgical retina care, including current management of age-related macular degeneration (AMD) and diabetic retinopathy, ocular imaging, gene therapy, ocular inflammation, surgical technologies, ocular oncology, and the latest advances in retinal pharmacotherapy.

**About Opthea**

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, [NCT04757636](#), and ShORe, [NCT04757610](#)) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at [www.opthea.com](http://www.opthea.com) and follow us on [X](#) and [LinkedIn](#)

Authorized for release to ASX by Frederic Guerard, CEO

---

**Investor Inquiries**

PJ Kelleher  
LifeSci Advisors LLC  
Email: [pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)  
Phone: [617-430 7579](tel:617-430-7579)

**Media Inquiries**

Silvana Guerri-Lena  
NorthStream Global Partners  
[silvana@nsgpllc.com](mailto:silvana@nsgpllc.com)

***Join our email database to receive program updates:***

Tel: +61 (0) 3 9826 0399  
Email: [info@opthea.com](mailto:info@opthea.com)  
Web: [www.opthea.com](http://www.opthea.com)

**Source: Opthea Limited**

---

